Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
FDMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.58 - $36.25
Previous CloseN/A
Volume165.32K
Average Volume (3M)826.48K
Market Cap
$181.51M
Enterprise Value$123.49M
Total Cash (Recent Filing)$149.34M
Total Debt (Recent Filing)$24.61M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 08, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.16
Shares Outstanding46,302,406
10 Day Avg. Volume702,468
30 Day Avg. Volume826,481
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4905.55
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.34K
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$33.40Price Target Upside752.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe gene therapy program is on the verge of pivotal trial initiations, highlighting a significant advancement for the company.
Financial HealthFDMT ended the year with $505M in cash, which is expected to fund operations into 2028, providing a strong financial foundation for future developments.
Safety Profile4D-150’s safety remains highly favorable with less than 3% of patients showing minimal inflammation and 99% remaining steroid-free.
Bears Say
Commercial DynamicsAnalyst's rating is predicated primarily on currently difficult-to-discern eventual commercial dynamics for an anti-VEGF gene therapy.
CompetitionThere is competition from other programs and possible retina business model disruption.
Program Delays4D-175, 4D-725, and 4D-310 remain paused pending additional financing or partnerships, indicating potential delays in these programs.
---
Ownership Overview
14.99% Insiders
13.25% Mutual Funds
1.41% Other Institutional Investors
58.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $3.58 and its highest was $36.25 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $181.51M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Feb 28, 2025. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.835 by -$0.055.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -0.86.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 46,302,406 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.835. Following the earnings report the stock price went down -8.609%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
---
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.40 (752.04% Upside)
$33.40 (752.04% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 624.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.40%
12-Months-Change
Fundamentals
Return on Equity
-25.95%
Trailing 12-Months
Asset Growth
67.04%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
---
FDMT Stock 12 Month Forecast
Average Price Target
$33.40
▲(752.04% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
5/19 ratings generated profit
1 Year Average Return
-23.10%
reiterated a buy rating 22 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -23.10% per trade.
---